Knowthestock.com
AGN - Allergan Plc

Sell

Weak GrowthEarnings/Profit is Negative

19%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 2.44%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -15.44%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.01
Debt Ratio is 0.34
Current Debt to Net Income Ratio is 5.16
Total Debt to Total Assets Ratio is 0.22
Cash Flow is STRONG
Cash from Operations Growth is 13.02%
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Allergan Plc (AGN) - http://www.allergan.com
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.
Exchange - New York Stock Exchange
Industry - Pharmaceuticals: Generic
Sector - Health Technology
CEO -
Employees - 17,400
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.